Embecta, a US-based pure-play diabetes care company, has forged a partnership with Tidepool to develop automated insulin delivery (AID) system for people having type 2 diabetes (T2D).
Tidepool is a 501(c)(3) nonprofit organisation in the US, which is focused on leveraging technology to offer intuitive software products that support diabetic people.
Established in 2013, Tidepool has a suite of software tools to offer diabetes patients and the clinics serving them. The tools include Tidepool Web, Tidepool Uploader, Tidepool Mobile, and Tidepool Loop.
Tidepool founder and CEO Howard Look said: “We are committed to helping all people with insulin-requiring diabetes safely achieve improved outcomes.
“Building on the recent FDA clearance for Tidepool Loop, Tidepool is excited to partner with embecta to create tailored solutions for a broader user base including people with type 2 diabetes.”
As part of the partnership, the Nasdaq-listed embecta will tap Tidepool’s know-how in software for diabetes management to develop an automated insulin delivery algorithm for its closed-loop patch pump system.
Embecta CEO Devdatt Kurdikar said: “By partnering with Tidepool and tapping into their expertise on AID software development, we’re continuing our effort to deliver a user-friendly patch pump solution that will make life better for people living with T2D.”
Embecta’s patch pump system is said to be designed to the precise requirements of type 2 diabetes patients. The closed-loop patch pump system has a breakthrough device designation from the US Food and Drug Administration (FDA).
The pure-play diabetes care company was formed via a spin-out of the diabetes care business of Becton, Dickinson and Company (BD) in 2022.
In a separate announcement, embecta said that its revenues for the second quarter of 2023 were $277.1m.
Source: Company Press Release
